Summary
Gilead Sciences, Inc. reported total revenues of $6.51 billion for the third quarter of 2017, a decrease of 13% from $7.50 billion in the prior year period, primarily driven by lower product sales in its antiviral segment, particularly Hepatitis C (HCV) treatments. While HIV and Hepatitis B (HBV) product sales showed resilience and growth driven by newer TAF-based regimens, the HCV franchise, including blockbuster drugs like Harvoni and Sovaldi, experienced a significant decline. This downturn is attributed to a rapid decrease in patient starts following widespread treatment and cures, coupled with increasing competition. The company also highlighted its significant acquisition of Kite Pharma for approximately $11.2 billion, aiming to establish a strong position in the rapidly growing cell therapy market with the approval of Yescarta. Despite revenue pressures in the core antiviral business, Gilead maintained a strong cash position and continued its share repurchase program.
Financial Highlights
57 data points| Revenue | $6.51B |
| Cost of Revenue | $1.03B |
| Gross Profit | $5.37B |
| R&D Expenses | $789.00M |
| SG&A Expenses | $879.00M |
| Operating Expenses | $2.70B |
| Operating Income | $3.81B |
| Interest Expense | $291.00M |
| Net Income | $2.72B |
| EPS (Basic) | $2.08 |
| EPS (Diluted) | $2.06 |
| Shares Outstanding (Basic) | 1.31B |
| Shares Outstanding (Diluted) | 1.32B |
Key Highlights
- 1Total revenues for Q3 2017 decreased by 13% to $6.51 billion compared to $7.50 billion in Q3 2016, mainly due to a 14% decrease in product sales to $6.40 billion.
- 2Antiviral product sales, particularly from HCV treatments like Harvoni and Sovaldi, significantly declined, while HIV and HBV product sales grew by 1% and 5% respectively (year-over-year for the nine-month period), driven by TAF-based products.
- 3Gilead completed the acquisition of Kite Pharma for approximately $11.2 billion, bolstering its presence in the cell therapy space with Yescarta, which received FDA approval in October 2017.
- 4Research and development expenses decreased by 31% to $789 million in Q3 2017 compared to $1.14 billion in Q3 2016, largely due to a significant milestone expense and impairment charge in the prior year.
- 5Net income attributable to Gilead was $2.72 billion ($2.06 per diluted share) for Q3 2017, down from $3.33 billion ($2.49 per diluted share) in Q3 2016, impacted by lower product sales and a higher effective tax rate.
- 6The company maintained a strong liquidity position with $41.4 billion in cash, cash equivalents, and marketable securities as of September 30, 2017.
- 7The company is facing significant patent litigation, most notably regarding its HCV products, with potential losses estimated between zero and $3.6 billion.